Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Crossref DOI link: https://doi.org/10.1007/s40273-017-0527-z
Published Online: 2017-06-15
Published Print: 2017-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Min http://orcid.org/0000-0003-1960-4552
Lou, Yanyan
Pellissier, James
Burke, Thomas
Liu, Frank Xiaoqing
Xu, Ruifeng
Velcheti, Vamsidhar
Funding for this research was provided by:
Merck & Co. Inc.
License valid from 2017-06-15